// App-Quantinova.ai

2917 : Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens

Researchers

Presenter

  • Rashmi Kanagal-Shamanna

Principal Investigators

  • Raja Luthra

  • Nitin Jain

  • Rebecca Garris

  • Sherry Pierce

  • Zeev Estrov

  • William G. Wierda

  • Susan M. -Brien

  • Jorge E. Cortes

  • Hagop M. Kantarjian

  • Elias J. Jabbour

  • Keyur P. Patel

  • Guillermo Garcia-Manero

  • Koichi Takahashi

  • Farhad Ravandi

  • Koji Sasaki

  • Tapan M. Kadia

  • Gautam Borthakur

  • Marina Konopleva

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • Hypercarotenemia and vitamin A deficiency

Biomarkers

  • Breakpoint Cluster Region

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved